10 news items
Takeda Canada Inc. concludes Letter of Intent (LOI) with the pan-Canadian Pharmaceutical Alliance (pCPA) for LIVTENCITY® (maribavir) for the treatment of adults with a post-transplant cytomegalovirus (CMV) infection
TAK
16 May 24
, and Gastroenterology (GI). We also make targeted R&D investments in Plasma-Derived Therapies and Vaccines. We are focusing on developing highly innovative
Scilex Holding Announce Final Court Approval Settlement Agreement With Takeda Pharmaceuticals To Resolve The Paragraph IV Patent Infringement Lawsuit
SCLX
TAK
14 May 24
"))))), an innovative revenue-generating company focused on acquiring, developing and commercializing non-opioid pain management products for the treatment of acute
AC Immune and Takeda Sign Exclusive Option and License Agreement for Active Immunotherapy Targeting Amyloid Beta for Alzheimer's Disease
ACIU
TAK
13 May 24
.
"As pioneers in the field of active immunotherapy, we are developing an innovative approach that could change
AC Immune and Takeda Sign Exclusive Option and License Agreement for Active Immunotherapy Targeting Amyloid Beta for Alzheimer's Disease
ACIU
TAK
13 May 24
in the field of active immunotherapy, we are developing an innovative approach that could change the treatment paradigm for Alzheimer's disease
Takeda Announces FY2023 Full Year Results and FY2024 Outlook, Affirming Commitment to Late-Stage Pipeline Development and Core Operating Profit Margin Expansion
TAK
9 May 24
approvals from the U.S. FDA in FY2023, Takeda's performance demonstrates the potential of our pipeline and our ability to bring our innovative medicines
66g15jz4uniimpt 1tl5z4czgfx4xybercgjrjtz6vmxj
TAK
22 Apr 24
Japan and toward the creation of innovative therapeutics
54iwh21ax0g4369quuj9a4qc2lguv6s99t50o0ng
TAK
27 Mar 24
gastrointestinal diseases is unwavering. Alongside our continuous work on innovative treatments within our gastroenterology portfolio, we recognize the significant
do1zcomu0xkwj9sqlk1pbv1ru454tohiu7jj jxycb
TAK
26 Mar 24
option specifically approved to treat this ultra-rare condition," said Yasushi Kajii, Head, R&D Japan Region at Takeda. "Developing innovative
6mkry566i8idl39neoet1meowqv8wdn9okmrs1lryynkj
TAK
26 Feb 24
esteemed history and global presence, we are honored to advance our vision of delivering highly innovative medicines and transformative care worldwide
cfwvtd4 nat5zguvyw
TAK
26 Feb 24
and Vaccines. We are focusing on developing highly innovative medicines that contribute to making a difference in people's lives by advancing the frontier
- Prev
- 1
- Next